TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00953368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning
Description: Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: remote ischemic preconditioning
Description: Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
Study: NCT04195152

Intervention type: OTHER
Intervention: Observational
Description: No intervention

Intervention type: OTHER
Intervention: Observational
Description: No intervention
Study: NCT01359709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Participants will apply Nicoderm (14 mg) patches everyday during this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine polacrilex
Description: Participants will apply Nicoderm (14 mg) patches everyday during this study.
Study: NCT00853671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adenosine Stress Dual-source CTP
Description: Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; Iopamidol (IV contrast)- total dose of 150cc; Siemens SOMATOM Definition CT scanner (CT scan radiation) - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)~This is an observational trial, and all patients will undergo the Adenosine Stress Dual-source CTP procedure.
Study: NCT03084536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: -Given after general anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: * As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: * As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: * As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: * As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: -As per routine care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: -As per routine care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: -As per routine care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: -As per routine care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: -As per routine care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: -As per routine care
Study: NCT02446522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic vein harvesting
Description: Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
Study: NCT01068847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-4 of the drugs listed below
Description: Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
Study: NCT02967874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular auto-SVFs injection
Description: Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
Study: NCT04052451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Subjects will take study medication once daily for the duration of the study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Subjects will take study medication once daily for the duration of the study
Study: NCT00507559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptus Endovascular AAA Repair System
Description: EVAR (endovascular aneurysm repair)
Study: NCT06068712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Cue Type
Description: Positive cue (target), negative cue (distractor), or neutral cue (baseline)
Study: NCT04674020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Study: NCT04449055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
Study: NCT02431351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
Study: NCT01290874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium bromide 18 mcg once daily for one year of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg twice daily for one year of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 mcg twice daily for one year
Study: NCT02532894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: Inhaling e-cigarette vapor
Study: NCT03754075

Intervention type: PROCEDURE
Intervention: Complete mesocolic excision
Description: The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.

Intervention type: PROCEDURE
Intervention: Conventional colon resections
Description: The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
Study: NCT02304107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
Study: NCT03080844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delay time to first cigarette
Description: Participants asked to delay time until they smoke first cigarette of the day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Participants receive tips on how to resist the urge to smoke and control cravings to smoke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
Study: NCT00616122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT03283826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATA188
Description: ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ATA188
Study: NCT03921424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
Study: NCT02587650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT02898532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational programmes
Description: Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
Study: NCT01246583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Ointment 1
Description: 2% CP-690,550 Ointment 1 twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle 1
Description: Vehicle 1 twice daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 Ointment 2
Description: 2% CP-690,550 Ointment 2 twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle 2
Description: Vehicle 2 twice daily for 4 weeks
Study: NCT01471782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered by continuous intravenous infusion
Study: NCT01696526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin D fortified fish
Description: fish containing vitamin D3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional fish
Description: fish containing low concentrations of vitamin D3
Study: NCT05054114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma human recombinant (IFN-G)
Description: nasal form
Study: NCT04203524

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin Levels
Description: Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
Study: NCT00584155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline and 0.3% ofloxacin
Description: The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's with 0.03% Ofloxacin
Description: The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
Study: NCT00349856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity
Description: Soft contact lens
Study: NCT02544711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific instrument
Description: The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional surgical treatment
Description: The conventional treatment is planned on two-dimensional images (CT and MRI).
Study: NCT03784079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK3640254 Mesylate salt
Description: Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK3640254 Mesylate salt
Description: Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
Study: NCT02231151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The type of CPR error(s) shown to the individual
Description: Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
Study: NCT03235648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiophrenic lymph nodes resection
Description: surgical resection
Study: NCT00128479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: mifepristone 300 mg daily for 7 dats

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mifepristone matched placebo
Description: daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 600 mg
Description: mifepristone 600 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 1200 mg
Description: mifepristone 1200 mg daily for 7 days
Study: NCT01443520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given orally placebo twice a day for 8 days prior to the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
Study: NCT03870438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Oral Solution
Description: In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
Study: NCT03488173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole capsules
Description: Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole capsules
Description: Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order.
Study: NCT03849417

Intervention type: OTHER
Intervention: ECT
Description: ECT administered as part of normal clinical management
Study: NCT01270308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole DR Capsules 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole DR Capsules 30 mg
Study: NCT00960336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study: NCT02459327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check Up
Description: FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
Study: NCT03581786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
Description: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo combine with chemotherapy
Study: NCT03151863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: The usual opioid treatment used for nursing care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is provided intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline is either given subcutaneously or intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline is either given subcutaneously or intranasally